CN1698587A - 一种来源于迷迭香的总二萜酚及其制备方法和用途 - Google Patents
一种来源于迷迭香的总二萜酚及其制备方法和用途 Download PDFInfo
- Publication number
- CN1698587A CN1698587A CN 200410042715 CN200410042715A CN1698587A CN 1698587 A CN1698587 A CN 1698587A CN 200410042715 CN200410042715 CN 200410042715 CN 200410042715 A CN200410042715 A CN 200410042715A CN 1698587 A CN1698587 A CN 1698587A
- Authority
- CN
- China
- Prior art keywords
- herba rosmarini
- rosmarini officinalis
- total diterpene
- phenol
- filtrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 229930004069 diterpene Natural products 0.000 title claims description 53
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 title claims description 46
- 150000004141 diterpene derivatives Chemical class 0.000 title claims description 43
- 241001529742 Rosmarinus Species 0.000 title abstract description 7
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims abstract description 33
- 239000000706 filtrate Substances 0.000 claims abstract description 26
- 239000003814 drug Substances 0.000 claims abstract description 25
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 14
- -1 diterpenoids phenols Chemical class 0.000 claims abstract description 12
- 239000000284 extract Substances 0.000 claims abstract description 12
- XUSYGBPHQBWGAD-PJSUUKDQSA-N Carnosol Chemical compound CC([C@@H]1C2)(C)CCC[C@@]11C(=O)O[C@@H]2C2=C1C(O)=C(O)C(C(C)C)=C2 XUSYGBPHQBWGAD-PJSUUKDQSA-N 0.000 claims abstract description 11
- MMFRMKXYTWBMOM-UHFFFAOYSA-N Carnosol Natural products CCc1cc2C3CC4C(C)(C)CCCC4(C(=O)O3)c2c(O)c1O MMFRMKXYTWBMOM-UHFFFAOYSA-N 0.000 claims abstract description 11
- 235000004654 carnosol Nutrition 0.000 claims abstract description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 206010006187 Breast cancer Diseases 0.000 claims abstract description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 7
- 238000005520 cutting process Methods 0.000 claims abstract description 6
- 238000001035 drying Methods 0.000 claims abstract description 6
- 150000002989 phenols Chemical class 0.000 claims abstract description 6
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims abstract description 4
- 238000001914 filtration Methods 0.000 claims abstract description 4
- 201000002313 intestinal cancer Diseases 0.000 claims abstract description 4
- 239000000463 material Substances 0.000 claims abstract 3
- 229940079593 drug Drugs 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 14
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 239000012567 medical material Substances 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 6
- 206010002383 Angina Pectoris Diseases 0.000 claims description 5
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 5
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 5
- 201000010881 cervical cancer Diseases 0.000 claims description 5
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 201000008275 breast carcinoma Diseases 0.000 claims description 4
- 210000000038 chest Anatomy 0.000 claims description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000007598 dipping method Methods 0.000 claims description 3
- 238000005325 percolation Methods 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 208000012991 uterine carcinoma Diseases 0.000 claims description 3
- 238000004061 bleaching Methods 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000002481 ethanol extraction Methods 0.000 claims description 2
- 238000000605 extraction Methods 0.000 abstract description 2
- 239000004615 ingredient Substances 0.000 abstract description 2
- 230000008569 process Effects 0.000 abstract description 2
- 206010000087 Abdominal pain upper Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000019065 cervical carcinoma Diseases 0.000 abstract 1
- 238000001816 cooling Methods 0.000 abstract 1
- 230000008859 change Effects 0.000 description 34
- 210000004027 cell Anatomy 0.000 description 19
- 230000002107 myocardial effect Effects 0.000 description 11
- 241000700159 Rattus Species 0.000 description 7
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 239000009465 diaoxinxuekang Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 4
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 4
- HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical group C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000000747 cardiac effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960004166 diltiazem Drugs 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000010298 pulverizing process Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- DOUMFZQKYFQNTF-WUTVXBCWSA-N (R)-rosmarinic acid Chemical compound C([C@H](C(=O)O)OC(=O)\C=C\C=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-WUTVXBCWSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 210000003516 pericardium Anatomy 0.000 description 2
- 238000000197 pyrolysis Methods 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- ZZAFFYPNLYCDEP-HNNXBMFYSA-N Rosmarinsaeure Natural products OC(=O)[C@H](Cc1cccc(O)c1O)OC(=O)C=Cc2ccc(O)c(O)c2 ZZAFFYPNLYCDEP-HNNXBMFYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 241000053227 Themus Species 0.000 description 1
- 108010093894 Xanthine oxidase Proteins 0.000 description 1
- 102100033220 Xanthine oxidase Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000003748 coronary sinus Anatomy 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003601 intercostal effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002932 luster Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000001589 microsome Anatomy 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229960002275 pentobarbital sodium Drugs 0.000 description 1
- 229940011964 pentobarbital sodium 30 mg Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000036581 peripheral resistance Effects 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- DOUMFZQKYFQNTF-MRXNPFEDSA-N rosemarinic acid Natural products C([C@H](C(=O)O)OC(=O)C=CC=1C=C(O)C(O)=CC=1)C1=CC=C(O)C(O)=C1 DOUMFZQKYFQNTF-MRXNPFEDSA-N 0.000 description 1
- TVHVQJFBWRLYOD-UHFFFAOYSA-N rosmarinic acid Natural products OC(=O)C(Cc1ccc(O)c(O)c1)OC(=Cc2ccc(O)c(O)c2)C=O TVHVQJFBWRLYOD-UHFFFAOYSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
组别 | 剂量mg/kg | 给药前 | 给药后 | ||||
30 | 60 | 120 | 150 | 240 | |||
溶媒对照组 | 116.17±29.095 | 113.38±31.724 | 113.38±31.724 | 107.30±27.613 | 109.06±32.549 | 105.43±28.256 | |
% | -2.79±9.557 | -2.79±9.557 | -7.49±8.997 | -6.78±10.143 | -9.21±11.643 | ||
地奥心血康 | 32 | 124.37±42.919 | 121.00±37.687 | 121.00±37.687 | 145.23±46.980 | 139.58±43.431 | 131.02±48.172 |
% | -1.70±5.675 | -1.70±5.675 | 18.32±17.712△△ | 13.57±13.164△ | 4.79±4.947△ | ||
实验组1 | 50 | 103.27±19.513 | 104.04±15.614 | 104.04±15.614 | 114.94±11.944 | 115.54±15.965 | 96.36±17.093 |
% | 1.55±6.798 | 1.55±6.798 | 13.35±15.165△ | 13.88±17.984△ | -6.52±5.625 | ||
实验组II | 100 | 125.17±29.010 | 125.01±26.906 | 125.01±26.906 | 145.46±21.873* | 138.61±25.498 | 134.67±23.304 |
% | 0.35±5.324 | 0.35±5.324 | 18.36±12.346△△ | 12.74±15.961△ | 9.99±17.584△ | ||
实验组III | 200 | 112.86±22.604 | 116.11±18.654 | 116.11±18.654 | 144.18±15.805* | 136.66±19.758 | 125.46±18.755 |
% | 3.88±7.290 | 3.88±7.290 | 31.92±27.872△△ | 23.56±18.876△△ | 13.43±17.428△ |
组别 | 剂量mg/kg | 给药前 | 给药后 | ||||
30 | 60 | 120 | 150 | 240 | |||
溶媒对照组 | 0.11±0.031 | 0.12±0.041 | 113.38±31.724 | 0.12±0.042 | 109.06±32.549 | 105.43±28.256 | |
% | -0.51±10.463 | -2.79±9.557 | 3.62±10.334 | -6.78±10.143 | -9.21±11.643 | ||
地奥心血康 | 32 | 0.12±0.036 | 0.11±0.032 | 121.00±37.687 | 0.09±0.029 | 139.58±43.431 | 131.02±48.172 |
% | -1.22±4.745 | -1.70±5.675 | -18.31±13.593△ | 13.57±13.164△ | 4.79±4.947△ | ||
实验组I | 50 | 0.14±0.031 | 0.13±0.024 | 104.04±15.614 | 0.11±0.018 | 115.54±15.965 | 96.36±17.093 |
% | -2.03±7.648 | 1.55±6.798 | -16.14±10.950△△ | 13.88±17.984△ | -6.52±5.625 | ||
实验组II | 100 | 0.11±0.028 | 0.11±0.026 | 125.01±26.906 | 0.09±0.015 | 138.61±25.498 | 134.67±23.304 |
% | -4.48±5.392 | 0.35±5.324 | -17.59±7.848△△ | 12.74±15.961△ | 9.99±17.584△ | ||
实验组III | 200 | 0.12±0.025 | 0.12±0.026 | 116.11±18.654 | 0.09±0.011 | 136.66±19.758 | 125.46±18.755 |
% | -5.45±10.358 | 3.88±7.290 | -27.16±15.484△△ | 23.56±18.876△△ | 13.43±17.428△ |
组别 | 三常 | 5s | 15s | 30s | 3min | |
空白 | 0.80±0.42 | 变化(mm) | 2.95±1.79 | 3.85±1.53 | 1.60±1.26 | 0.95±1.12 |
变化率(%) | 417±346 | 498±287 | 237±219 | 122±130 | ||
合心爽 | 0.67±0.45 | 变化(mm) | 0.53±0.75** | 0.92±0.93** | 1.07±0.92 | 0.80±0.75 |
变化率(%) | 94±147* | 119±122** | 169±119 | 88±83 | ||
地奥心血康200mg/kg | 0.70±0.63 | 变化(mm) | 1.90±1.54 | 1.90±1.71* | 1.25±0.95 | 0.95±0.69 |
变化率(%) | 257±239 | 246±203* | 161±178 | 79±70 | ||
迷迭香总二萜酚600mg/kg | 0.60±0.46 | 变化(mm) | 0.90±1.35** | 1.55±1.48** | 1.8±1.7 | 0.7±0.42 |
变化率(%) | 186±318 | 129±49** | 164±138 | 86±48 | ||
迷迭香总二萜酚300mg/kg | 0.90±0.74 | 变化(mm) | 1.00±1.22 | 2.7±2.08 | 1.40±1.07 | 0.95±0.69 |
变化率(%) | 114±111* | 250±165* | 125±109 | 100±76 | ||
迷迭香总二萜酚150mg/kg | 0.80±0.79 | 变化(mm) | 1.25±1.27 | 2.45±1.66 | 1.55±1.30 | 1.30±0.86 |
变化率(%) | 181±152 | 306±207 | 117±98 | 117±113 |
组别 | 正常 | 5s | 15s | 30s | 3min | |
空白 | 1.80±0.35 | 变化(mm) | 2.05±1.96 | 2.80±2.12 | 1.1±1.17 | 0.25±0.42 |
变化率(%) | 108±99 | 162±125 | 73±93 | 13±22 | ||
合心爽 | 1.65±0.34 | 变化(mm) | 0.45±0.37* | 0.55±0.37** | 0.75±0.35 | 0.3±0.35 |
变化率(%) | 30±30* | 33±21** | 48±29 | 20±22 | ||
地奥心血康200mg/kg | 1.85±0.47 | 变化(mm) | 1.05±0.90 | 0.85±1.00* | 0.65±0.63 | 0.40±0.39 |
变化率(%) | 61±53 | 54±69* | 32±29 | 25±31 | ||
迷迭香总二萜酚600mg/kg | 2.05±0.50 | 变化(mm) | 0.65±0.91 | 0.35±0.82** | 0.55±0.50 | 0.55±0.50 |
变化率(%) | 32±45 | 17±40 | 27±24 | 27±24 | ||
迷迭香总二萜酚300mg/kg | 2.00±0.41 | 变化(mm) | 0.75±0.92 | 1.05±1.36* | 0.50±0.47 | 0.35±0.41 |
变化率(%) | 40±56 | 53±68* | 25±23 | 18±19 | ||
迷迭香总二萜酚150mg/kg | 1.7±0.75 | 变化(mm) | 0.75±0.68 | 1.60±1.26 | 0.55±0.50 | 0.60±0.77 |
变化率(%) | 50±47 | 101±73 | 32±31 | 32±34 |
Claims (10)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410042715XA CN1297259C (zh) | 2004-05-21 | 2004-05-21 | 一种来源于迷迭香的总二萜酚及其制备方法和用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB200410042715XA CN1297259C (zh) | 2004-05-21 | 2004-05-21 | 一种来源于迷迭香的总二萜酚及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1698587A true CN1698587A (zh) | 2005-11-23 |
CN1297259C CN1297259C (zh) | 2007-01-31 |
Family
ID=35474940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB200410042715XA Expired - Fee Related CN1297259C (zh) | 2004-05-21 | 2004-05-21 | 一种来源于迷迭香的总二萜酚及其制备方法和用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1297259C (zh) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007113291A3 (en) * | 2006-04-03 | 2008-09-18 | Nestec Sa | Nutritional compositions for promotion of bone growth and maintenance of bone health and methods regarding same |
CN102697758A (zh) * | 2012-06-12 | 2012-10-03 | 昆明理工大学 | 柳杉醇在制备抗肿瘤血管异常新生药物中的应用 |
CN104530074A (zh) * | 2015-01-07 | 2015-04-22 | 浙江泰康生物科技有限公司 | 一种从鼠尾全草中提取鼠尾草酚的方法 |
WO2016037250A1 (pt) * | 2014-09-11 | 2016-03-17 | Universidade Estadual De Campinas - Unicamp | Processo de purificação de extrato de jambu, extrato purificado assim obtido, composição anestésica e bioadesivo contendo extrato purificado de jambu; e usos |
CN112367848A (zh) * | 2018-06-14 | 2021-02-12 | 马斯公司 | 用于支持患有癌症的动物的组合物 |
CN113244222A (zh) * | 2020-02-12 | 2021-08-13 | 华东师范大学 | 鼠尾草酚类化合物在制备治疗恶病质疾病的药物中的应用 |
CN116270798A (zh) * | 2023-02-07 | 2023-06-23 | 中国科学院植物研究所 | 迷迭香提取物在协同uv辐射抑制多种癌细胞增殖、促进凋亡中的用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69033299T2 (de) * | 1990-10-06 | 2000-01-05 | Societe Des Produits Nestle S.A., Vevey | Verwendung von Carnosolsäure wegen seiner anticarcinogenen und antiviralen Eigenschaften |
CN1076380C (zh) * | 1995-01-13 | 2001-12-19 | 金坚敏 | 来自于迷迭香的高效天然抗氧化剂和其制备方法 |
CN1327038A (zh) * | 2001-07-18 | 2001-12-19 | 孙传经 | 超临界co2反向萃取法提取迷迭香抗氧化剂的方法 |
CN1304023C (zh) * | 2003-09-26 | 2007-03-14 | 上海市新文达生物科技有限公司 | 迷迭香提取物在制药中的应用 |
-
2004
- 2004-05-21 CN CNB200410042715XA patent/CN1297259C/zh not_active Expired - Fee Related
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007113291A3 (en) * | 2006-04-03 | 2008-09-18 | Nestec Sa | Nutritional compositions for promotion of bone growth and maintenance of bone health and methods regarding same |
CN102697758A (zh) * | 2012-06-12 | 2012-10-03 | 昆明理工大学 | 柳杉醇在制备抗肿瘤血管异常新生药物中的应用 |
WO2016037250A1 (pt) * | 2014-09-11 | 2016-03-17 | Universidade Estadual De Campinas - Unicamp | Processo de purificação de extrato de jambu, extrato purificado assim obtido, composição anestésica e bioadesivo contendo extrato purificado de jambu; e usos |
CN104530074A (zh) * | 2015-01-07 | 2015-04-22 | 浙江泰康生物科技有限公司 | 一种从鼠尾全草中提取鼠尾草酚的方法 |
CN112367848A (zh) * | 2018-06-14 | 2021-02-12 | 马斯公司 | 用于支持患有癌症的动物的组合物 |
CN113244222A (zh) * | 2020-02-12 | 2021-08-13 | 华东师范大学 | 鼠尾草酚类化合物在制备治疗恶病质疾病的药物中的应用 |
CN113244222B (zh) * | 2020-02-12 | 2022-10-25 | 华东师范大学 | 鼠尾草酚类化合物在制备治疗恶病质疾病的药物中的应用 |
CN116270798A (zh) * | 2023-02-07 | 2023-06-23 | 中国科学院植物研究所 | 迷迭香提取物在协同uv辐射抑制多种癌细胞增殖、促进凋亡中的用途 |
Also Published As
Publication number | Publication date |
---|---|
CN1297259C (zh) | 2007-01-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1237961C (zh) | 二苯乙烯类化合物在制备用于治疗和预防糖尿病或与逆转录病毒有关疾病的药物中用途 | |
CN1297259C (zh) | 一种来源于迷迭香的总二萜酚及其制备方法和用途 | |
CN105250366B (zh) | 香青兰提取物及其制备方法和用途 | |
TW201618801A (zh) | 用於輔助化療藥物之醫藥組合物及其用途 | |
CN103006769B (zh) | 一种治疗心脑血管疾病的中药组合物及其制备方法 | |
CN101485694B (zh) | 一种灵芝三萜类成分的提取方法 | |
CN112353877B (zh) | 缬草总生物碱提取物在制备马拉色菌抑制剂中的用途 | |
CN1257918C (zh) | 麦冬多糖mdg-1及其分离方法和应用 | |
CN101229223B (zh) | 补骨脂提取物在制备抗肿瘤药物中的应用 | |
CN101028328A (zh) | 柿叶提取物的制备及应用 | |
CN1895307A (zh) | 一种治疗心脑血管疾病的中药提取物和其制备方法及其用途 | |
CN103933541B (zh) | 一种谷胱甘肽抗癌组合物 | |
CN109806304A (zh) | 三叶悬钩子植物提取物及其药物组合物的制备方法与抗旋毛虫用途 | |
CN1291735C (zh) | 一种活血化瘀,行气止痛的中药滴丸制剂 | |
CN1907312A (zh) | 鹅不食草挥发油在制备肿瘤生长和增殖的抑制剂中的应用 | |
CN100408042C (zh) | 灵芝酸t在制备肿瘤生长或增殖抑制剂中的应用 | |
CN1282467C (zh) | 一种治疗冠心病和心绞痛的药物及其制备方法 | |
CN1246326C (zh) | 化合物菠萝黄酮苷及用途 | |
CN1176677C (zh) | 一种治疗冠心病的中药组合物及其制剂和制备方法 | |
CN1981832A (zh) | 栀子提取物在治疗慢性乙型肝炎中的用途 | |
CN101062895A (zh) | 异菊苣酸及其提取分离方法和在药物中的用途 | |
CN1660378A (zh) | 菊花有效部位的应用 | |
CN108997473A (zh) | 一种非海参烷型海参皂苷及其制备方法与应用 | |
CN103202867A (zh) | 昆仑雪菊在制备降血压药物中的应用 | |
CN1879764A (zh) | 一种鸢尾的医药用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: GUANGZHOU BAIYUNSHAN CHINESE HUTCHISON WHAMPOA LT Free format text: FORMER OWNER: BEIJING HUAYI SHENNONG MEDICINE TECHNOLOGY CO., LTD. Effective date: 20080711 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20080711 Address after: No. 389 Sha ha North Road, Baiyun District, Guangzhou Patentee after: HUTCHISON WHAMPOA GUANGZHOU BAIYUNSHAN CHINESE MEDICINE Co.,Ltd. Address before: Room 4, layer 411, building 38, Xueyuan Road, Beijing Patentee before: Beijing Huayi Shennong Pharmaceutical Technology Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070131 |